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Abstract
Objective—Chromosome 22q11.2 deletion syndrome is a neurogenetic disorder associated with 
high rates of schizophrenia and other psychiatric conditions. The authors report what is to their 
knowledge the first large-scale collaborative study of rates and sex distributions of psychiatric 
disorders from childhood to adulthood in 22q11.2 deletion syndrome. The associations among 
psychopathology, intellect, and functioning were examined in a subgroup of participants.
Method—The 1,402 participants with 22q11.2 deletion syndrome, ages 6–68 years, were 
assessed for psychiatric disorders with validated diagnostic instruments. Data on intelligence and 
adaptive functioning were available for 183 participants ages 6 to 24 years.
Results—Attention deficit hyperactivity disorder (ADHD) was the most frequent disorder in 
children (37.10%) and was overrepresented in males. Anxiety disorders were more prevalent than 
mood disorders at all ages, but especially in children and adolescents. Anxiety and unipolar mood 
disorders were overrepresented in females. Psychotic disorders were present in 41% of adults over 
age 25. Males did not predominate in psychotic or autism spectrum disorders. Hierarchical 
regressions in the subgroup revealed that daily living skills were predicted by the presence of 
anxiety disorders. Psychopathology was not associated with communication or socialization skills.
Conclusions—To the authors' knowledge, this is the largest study of psychiatric morbidity in 
22q11.2 deletion syndrome. It validates previous findings that this condition is one of the strongest 
risk factors for psychosis. Anxiety and developmental disorders were also prevalent. These results 
highlight the need to monitor and reduce the long-term burden of psychopathology in 22q11.2 
deletion syndrome.
Chromosome 22q11.2 deletion syndrome, also known as velocardiofacial or DiGeorge 
syndrome, is a neurogenetic condition affecting 1 in 2,000–4,000 live births and caused in 
most cases by a hemizygous 3-megabase microdeletion on the long arm of chromosome 22. 
Its phenotypic expression is highly variable and ranges from severe life-threatening 
conditions to only a few features. Frequently associated medical conditions include 
conotruncal cardiac anomalies, palatal anomalies (including velopharyngeal insufficiency), 
hypoparathyroidism/hypocalcemia, and subtle dysmorphic facial features (1). The 
neurocognitive profile is also highly variable, both between individuals and during the 
course of development (2). From infancy onward, motor delays (often with hypotonia) and 
speech or language deficits are commonly observed (3). During the preschool and primary 
Schneider et al. Page 2






















school ages, learning difficulties are very common. The majority of patients with 22q11.2 
deletion syndrome have an intellectual level that falls in the borderline range (IQ, 70–84), 
and about one-third have mild to moderate intellectual disability (3, 4). More severe levels 
of intellectual disability are uncommon in children and adolescents (4) but are more frequent 
in adults (5).
Psychiatric phenotypes of the syndrome have been described worldwide, and affected 
individuals have substantially greater rates of various psychiatric disorders than are found in 
the general population. Early studies focused on adults and consistently showed a greater 
than average prevalence (23%243%) of schizophrenia spectrum disorders (6–12). Therefore, 
22q11.2 deletion syndrome is currently recognized as a genetic model for understanding the 
development of schizophrenia.
Studies of children and adolescents with 22q11.2 deletion syndrome also show a heightened 
frequency of schizophrenia spectrum features and disorders, indicating that psychosis is a 
clinical characteristic of this syndrome even in pediatric groups (8, 12–25). These reports 
also highlight the high frequencies of anxiety disorders (40%–76%) and mood disorders 
(9%–35%), especially major depressive disorder, relative to the general population. 
Disorders typically diagnosed during childhood and adolescence have also been noted: 
attention deficit hyperactivity disorder (ADHD, 12%–68%), oppositional defiant disorder 
(9%–43%), and autism spectrum disorders (14%–50%). Other psychiatric disorders, such as 
substance use disorders or conduct disorder, have been less studied but do not appear to be 
unusually common in this population.
Despite elucidating several important aspects of the 22q11.2 deletion syndrome psychiatric 
phenotype, this body of evidence is inconsistent regarding the frequency of several 
disorders, probably because of the small number of subjects in most studies, differences in 
ascertainment sources, and cultural biases. Furthermore, we know of no study that has 
investigated the patterns of comorbidity across diagnostic categories and developmental 
stages in this population. Small numbers of subjects have largely precluded the examination 
of multiple age groups within the same study. To our knowledge, this was performed only in 
our earlier cross-sectional study on psychiatric morbidity in 22q11.2 deletion syndrome, 
which appears to be the largest to date (8). That two-center collaboration revealed that the 
prevalence of schizophrenia spectrum disorders linearly increased with age, while the 
frequency of mood disorders peaked in early adulthood. That study also demonstrated 
stability in the frequency of anxiety disorders and a linear decrease with age in the rates of 
ADHD and oppositional defiant disorder.
In the general population, the base rates for most disorders vary by sex. However, sex 
differences in the rates of psychiatric disorders remain largely unknown in 22q11.2 deletion 
syndrome. Preliminary data suggest that the sex distributions of some disorders may differ 
in this population from those typically observed (8, 24, 26). Finally, little is known about the 
impact of psychopathology on outcome in 22q11.2 deletion syndrome. Several studies 
indicated that schizophrenia spectrum disorders were associated with poorer outcome, 
whereas findings were less consistent for mood and anxiety disorders (22, 27, 28).
Schneider et al. Page 3






















The International Consortium on Brain and Behavior in 22q11.2 Deletion Syndrome has 
gathered cohorts from North America, Europe, Australia, and the Middle East. Although the 
studies were developed independently, the participating sites have collaborated, sharing 
knowledge and data (1, 29). Here we report on the prevalence of psychiatric disorders across 
the lifespan in 1,402 individuals with 22q11.2 deletion syndrome. Patterns of comorbidity 
across diagnostic categories were also explored. Another goal was to identify whether the 
sex distributions of psychiatric disorders are similar to the pattern observed in the general 
population. Finally, we examined the association of psychiatric disorders, intellectual 
functioning, and adaptive functioning in a subgroup of individuals.
Method
Participants
Participants were recruited across 15 sites (see Table 1). They were included if they had a 
genetically confirmed 22q11.2 microdeletion, were between the ages of 6 and 70 years, and 
underwent a comprehensive structured psychiatric assessment using a validated instrument. 
The following exclusion criteria were applied: normal or inconclusive genetic testing (N=2), 
missing demographic information (N=64), age less than 6 years (N=9), nonstructured 
clinical psychiatric assessment (N=146), assessment for a single disorder (e.g., autism 
spectrum disorder) (N=27), and assessment with self- or parent-report questionnaire 
(N=342).
The final study group consisted of 1,402 participants ages 6–68 years (mean=18.78, 
SD=10.66) (Figure 1). Females were over-represented (53.00% versus 47.00%, p=0.04), 
owing to a higher proportion among adults (N=600, 56.00% versus 44.00%, p=0.05), which 
was not the case in children and adolescents (N=802; 51.00% versus 49.00%, p=0.81). The 
study group was divided into five age groups: children (age 6–12 years, mean=9.50, 
SD=1.92; N=456), adolescents (age 13–17 years, mean=14.97, SD=1.37; N=346); emerging 
adults (age 18–25 years, mean=20.72, SD=2.18; N=323), young adults (age 26–35 years, 
mean=29.95, SD=2.95; N=150), and mature adults (age ≥36 years, mean=44.41, SD=7.13; 
N=127).
The ascertainment sources were heterogeneous: 40.22% of the patients were referred from 
nonmedical sources (28.10% through family association, 3.92% by relatives) or self-referred 
(8.20%), and 44.30% were referred by medical sources (department of genetics, 32.03%; 
psychiatry, 4.42%; cardiology, 5.49%; pediatrics, 2.35%). Referrals from departments of 
psychiatry were more frequent with increasing age (χ2=105.83, df=4, p<0.001).
Each site received approval from its local ethics committee (institutional review board). 
Each participant and his or her legal caregiver, where appropriate, gave written informed 
consent for study participation.
Psychiatric Diagnostic Assessment
Assessments were performed by using well-validated instruments widely used in psychiatric 
research (Table 1). Current diagnoses compatible with DSM-IV-TR diagnostic criteria were 
obtained. As participants' age and assessment instruments varied, not all disorders were 
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assessed for each cohort (see Table S1 in the data supplement accompanying the online 
version of this article). Schizophrenia spectrum, anxiety, and mood disorders were assessed 
in 1,292 participants (92.15% of the study group), and these findings were used for 
comorbidity analyses.
Intellectual and Adaptive Functioning
Measures of intellectual and adaptive functioning were available in a subgroup of 183 
participants ages 6–24 years (mean=14.25, SD=4.55), representing 13.05% of the total 
group (Table 1). About half of the patients in this subgroup were female (N=93, 50.82%).
Intellectual functioning was assessed by using the Wechsler scales. As different versions of 
the scales were used, the full-scale IQ was used as a global measure of intellectual 
functioning. One child was assessed with the Wechsler Preschool and Primary Scale of 
Intelligence (WIPPSI-R); 123 individuals were assessed with the Wechsler Intelligence 
Scale for Children, either the WISC-R (N=1) or WISC-III (N=122); 56 were assessed with 
the Wechsler Adult Intelligence Scale (WAIS-III); and two were assessed with the Wechsler 
Abbreviated Scale of Intelligence (WASI). Adaptive functioning was assessed by using the 
Vineland Adaptive Behavior Scales, a semistructured interview conducted with the 
caregiver(s) of the participant. This scale provides age-adjusted standardized scores 
(mean=100, SD=15) in the domains of communication, daily living skills, and socialization 
(40).
Statistical Analyses
Prevalences of psychiatric disorders were compared in the five age groups by means of chi-
square tests. Disorders typically diagnosed during childhood (i.e., ADHD, oppositional 
defiant disorder, conduct disorder, and autism spectrum disorders) were examined in a 
limited number of adults, and so adults were combined into a single group for these 
analyses. Binomial tests were used to identify sex differences in the rates of psychiatric 
disorders. Odds ratios were obtained to investigate patterns of comorbidity. Finally, the 
associations among psychiatric disorders, intellectual functioning, and adaptive functioning 
were examined by using analyses of covariance, Pearson correlations, and hierarchical 
regressions. For hierarchical regressions, one model was computed for each Vineland 
domain: age and full-scale IQ were entered in the first block and the presence of 
schizophrenia spectrum, anxiety, or mood disorders was entered in the second block. All 
statistical analyses were performed with SPSS version 19 (IBM, Armonk, N.Y.), except for 
calculation of odds ratios, which was performed by using the Medcalc online calculator 
(MedCalc Software, Ostend, Belgium; http://www.medcalc.org/).
Results
Prevalence of Psychiatric Disorders
Disorders typically diagnosed in childhood—The rates of disorders typically 
diagnosed during childhood were examined in children, adolescents, and the combined adult 
groups (Table 2, bottom). A higher percentage of children than adolescents met the 
diagnostic criteria for ADHD. Similarly, the prevalence was higher in adolescents than in 
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adults. A description of the ADHD subtype was available for 79.05% of the individuals with 
ADHD (200 of 253): 63.00% met the diagnostic criteria for the inattentive subtype, 6.50% 
for the hyperactive-impulsive subtype, and 30.50% for the combined subtype. ADHD was 
more prevalent in males (60.87%) than females (13.13%) (binomial test, p=0.001).
Rates of disruptive disorders (oppositional defiant disorder and conduct disorder) remained 
stable with age, ranging between about 7% and 14% of cases depending on the age group. 
The majority of participants with a disruptive disorder (89 of 91) were diagnosed with 
oppositional defiant disorder. Disruptive disorders were more frequent in males (63.74%) 
than females (36.26%) (binomial test, p=0.02).
The prevalence of autism spectrum disorders (autistic disorder, Asperger's syndrome, and 
pervasive developmental disorder not otherwise specified) differed among age groups and 
was highest among adolescents. There was no significant gender difference (p=0.77).
Mood and anxiety disorders—The frequency of major depressive disorder significantly 
increased with age, whereas dysthymia peaked in emerging adults (Table 2). Unipolar 
disorders (major depressive disorder and dysthymia) were overrepresented in females 
(61.18%) (binomial test, p=0.007). This difference was significant in adults (69.79% of 
females; binomial test, p<0.001) but not in children and adolescents (46.43% of females; 
p=0.69). Although the prevalence of bipolar disorders increased over the age groups, 
absolute numbers were small even in adults.
Anxiety disorders were common at all age groups (30.57% of the total group, 395 of 1,292) 
but were more frequent in children and adolescents than in the three adult groups. Across the 
entire study group, anxiety disorders were more frequent in females (57.22%) (binomial test, 
p=0.005). This difference was significant in adults (61.54% of females, binomial test, 
p=0.007) but not in children and adolescents (54.76% of females, p=0.15). Among the 395 
participants with an anxiety disorder, 69.11% met the diagnostic criteria for one anxiety 
disorder, 22.03% for two, and 9.11% for three or more disorders. The rates of obsessive-
compulsive disorder and generalized anxiety disorder were similar across age groups. The 
prevalences of specific phobia, social phobia, and separation anxiety disorder decreased with 
age. Panic disorder significantly increased with age. Posttraumatic stress disorder was rarely 
diagnosed (0.87% overall, eight of 918 participants).
Substance-related disorders—The prevalence of substance-related disorders was low 
in this group (Table 2). Alcohol abuse or dependence was diagnosed in 13 of the 22 subjects 
with reported substance use disorders; drug use disorders were rare.
Schizophrenia spectrum disorders—Schizophrenia spectrum disorders included the 
following disorders from the “schizophrenia and other psychotic disorders” section of the 
DSM-IV-TR: schizophrenia, schizophreniform disorder, schizoaffective disorder, delusional 
disorder, brief psychotic disorder, and psychotic disorder not otherwise specified. Mood 
disorders with psychotic features (e.g., bipolar disorder with psychotic features) were not 
included in this category.
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The prevalence of schizophrenia spectrum disorders significantly increased over the five age 
groups (Table 2). The prevalence of schizophrenia spectrum disorders was 23.53% in 
emerging adults and approximately 41% in the two groups over 25 years of age (Table 2, 
Figure 2). Findings were similar for schizophrenia and schizoaffective disorder combined 
(χ2=215.94, df=4, p<0.001), where the prevalence was 14.09% in emerging adults, 35.61% 
in young adults, and 33.96% in mature adults. There was no sex difference in the prevalence 
of psychotic disorders (p=0.24).
The distributions of the different forms of psychotic disorders varied across age groups 
(Figure 2). Among the 235 subjects diagnosed with a psychotic disorder, the prevalence of a 
diagnosis of schizophrenia increased over the five age groups, whereas the diagnosis of 
psychotic disorder not otherwise specified decreased. The prevalence of schizoaffective 
disorder was not significantly different among age groups. Other psychotic disorders were 
rarely diagnosed.
Comorbidity
The patterns of comorbidity among schizophrenia spectrum, anxiety, and mood disorders 
revealed a significant association between mood and anxiety disorders in that the presence 
of an anxiety disorder increased the likelihood of a mood disorder, with an odds ratio of 2.50 
(95% confidence interval [CI]: 1.75–3.57; p<0.001). Having an anxiety disorder also 
increased the likelihood of having comorbid diagnoses of both a mood disorder and a 
schizophrenia spectrum disorder (odds ratio: 6.07, 95% CI: 2.15–17.15; p<0.001). Similarly, 
being diagnosed with a mood disorder significantly increased the probability of having 
comorbid diagnoses of both an anxiety disorder and a schizophrenia spectrum disorder (odds 
ratio: 2.73, 95% CI: 1.43–5.22; p=0.002).
Associations Among Intellectual Functioning, Adaptive Functioning, and Psychiatric 
Disorders
Measures of intellectual and adaptive functioning were available for a subgroup of 183 
participants ages 6–24 years (mean=14.25, SD=4.55; 50.82% female [N=93]), representing 
13.05% of the total group.
The mean full-scale IQ was 71.25 (SD=12.13). There were 84 individuals (45.90%) with a 
full-scale IQ below 70, consistent with intellectual disability. The mean scores for the 
Vineland domains were approximately two standard deviations below the means of the 
general population (communication: mean=69.68, SD=14.14; daily living skills: 
mean=68.95, SD=16.38; socialization: mean=72.35, SD=14.68), corresponding to a 
moderate degree of impairment. Pearson correlations between full-scale IQ and the Vineland 
domains revealed significant and positive associations (p<0.001 in all cases). Intellectual 
functioning explained between 7.6% and 14.4% of the variance in adaptive functioning. Age 
was not significantly associated with intellectual functioning (r=0.06, p=0.42). Age was, 
however, negatively associated with the Vineland communication (r=−0.20, p=0.006) and 
socialization (r=−0.25, p=0.001) domains, and it was positively associated with the daily 
living skills domain (r=0.15, p<0.05).
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One-way analyses of covariance with age as a covariate revealed that individuals with a 
schizophrenia spectrum disorder (N=10) had a significantly lower full-scale IQ than those 
without a schizophrenia spectrum disorder (F=14.06, df=1, 180, p<0.001). In contrast, 
individuals with an anxiety (N=74) or a mood (N=17) disorder did not differ from those 
without an anxiety or mood disorder, respectively, on full-scale IQ (p>0.05 in both cases).
Hierarchical regressions revealed that communication and socialization skills were 
significantly predicted by age and full-scale IQ (Table 3). Daily living skills were 
significantly predicted by full-scale IQ and the presence of an anxiety disorder. The 
presence of a schizophrenia spectrum disorder had a nearly significant effect.
Discussion
The present study is an international collaborative investigation of 22q11.2 deletion 
syndrome, a genetic syndrome widely recognized as a model for schizophrenia. The 
inclusion of more than 1,400 participants makes it, to the best of our knowledge, the largest 
study to date on the frequency of psychiatric disorders throughout the lifespan.
Disorders Typically Diagnosed in Childhood
ADHD was diagnosed in 37.10% of children and was the most common diagnosis at this 
age. Although ADHD was less frequent in adults (15.59%), the rate was still higher than for 
adults in the general population (4.40%) (41). Consistent with findings in a recent 
longitudinal study (42), this suggests that ADHD persists until adulthood in many 
individuals with 22q11.2 deletion syndrome. In most cases the inattentive subtype prevailed, 
confirming findings from previous studies (43). This pattern contrasts with data from the 
general population and individuals with intellectual disability, which indicate a 
predominance of the combined subtype (44). It is still debated in the literature whether 
predominantly inattentive ADHD is a separate disorder, rather than a subtype of ADHD. 
Indeed, some data point toward specific neurobiological and environmental factors leading 
to the development of predominantly inattentive ADHD (45).
The prevalence of oppositional defiant disorder was slightly higher than in the general 
population but was similar to what has been described in youth with intellectual disability 
(46, 47). In our experience, individuals diagnosed with oppositional defiant disorder show a 
higher degree of impairment within the family, whereas they are often described as 
introverted by people outside the family. Future investigators may wish to compare these 
results with teacher reports of behavioral difficulties. Compared with oppositional defiant 
disorder, conduct disorder was rarely diagnosed, suggesting that severe externalizing 
disorders are underrepresented in 22q11.2 deletion syndrome.
Autism spectrum disorders were frequent in all age groups but peaked during adolescence. 
This was unexpected, as the prevalence is typically lower in adolescents than in younger 
groups from the general population. Several factors could explain this result. First, the 
prevalence of autism spectrum disorders was based on a subgroup of participants (N=548, 
39% of the study group), as appropriate diagnostic instruments were used in seven cohorts 
only. This may have increased the variability of the results among the age groups. Second, 
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the rate of autism spectrum disorders was highly variable among the cohorts, ranging from 
0% (Rome cohort) to 80% (Maastricht cohort assessed with the Mini PAS-ADD). In the 
adolescent group, 72% of the participants diagnosed with autism spectrum disorders 
belonged to the Utrecht cohort, a group with a high rate of autism spectrum disorders (54%). 
The variation may be due to differences in ascertainment referral, intellectual functioning, 
and/or assessment tools. Indeed, only three cohorts based the diagnosis on both the Autism 
Diagnostic Interview–Revised and the Autism Diagnostic Observation Schedule, which are 
the gold standards for the assessment of autism spectrum disorders. Third, it may be the case 
that at least a subgroup of adolescents with 22q11.2 deletion syndrome display a symptom 
pattern that resembles autism and is characterized in part by social deficits (48). This would 
be in agreement with previous findings from dimensional studies that showed impaired 
social functioning in children and adolescents with 22q11.2 deletion syndrome (22, 49). 
Also, a decrease in social functioning during adolescence may be an early marker for the 
development of psychosis in this population, as it is in the general population (50). Future 
studies are needed to better delineate the social phenotype in 22q11.2 deletion syndrome and 
its association with the onset of psychosis.
Altogether, these results indicate that 22q11.2 deletion syndrome is characterized by social 
deficits and attentional disturbances without prominent conduct disorder. This pattern of 
deficits has been previously described as part of the core neuropsychiatric phenotype of 
22q11.2 deletion syndrome (51).
Mood and Anxiety Disorders
Anxiety disorders were more prevalent than mood disorders at all ages, especially in 
pediatric age groups. Furthermore, mood and anxiety disorders had a distinct developmental 
trajectory, consistent with findings in previous studies (6, 8). As in the general population, 
mood and anxiety disorders were common comorbidities.
Previous studies have suggested that mood disorders emerging in young adults may be 
related to difficulties achieving social integration and independence and/or deviant 
trajectories of brain maturation during adolescence in areas underlying mood regulation (8, 
52). The prevalence of bipolar disorders does not appear to be higher in individuals with 
22q11.2 deletion syndrome than in the general population, a pattern consistent with findings 
in previous smaller studies (6, 8, 14, 15, 19). It does contrast with very early reports of the 
psychiatric phenotype in 22q11.2 deletion syndrome, which indicated bipolar disorders in 
small cohorts (7, 53). It is possible that some individuals with 22q11.2 deletion syndrome 
experience periods of mood lability without meeting criteria for a full manic or hypomanic 
episode.
Anxiety disorders were especially prevalent among children and adolescents. Our data 
highlighted the severity of anxiety in at least some individuals, as one-third of the 
participants with an anxiety disorder qualified for multiple anxiety disorders. Generalized 
anxiety disorder, specific phobia, and social phobia were the most frequent anxiety disorders 
during childhood and adolescence. Whereas the rate of specific phobia is similar to that in 
individuals with intellectual disability, social phobia and generalized anxiety disorder appear 
to be overrepresented in 22q11.2 deletion syndrome (46). This finding, combined with the 
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high rate of autism spectrum disorders, indicates that difficulties in the social domain may 
represent key characteristics of the syndrome (51). A novel finding relates to the high rate of 
panic disorder among adults (14% in mature adults). Some authors have suggested that 
panic disorder may be associated with the development of schizophrenia in the general 
population (54). This warrants further investigation in 22q11.2 deletion syndrome.
Schizophrenia Spectrum Disorders
The results are in accordance with previous studies showing that a 22q11.2 deletion is the 
strongest known molecular risk factor for schizophrenia. Indeed, the rates of psychotic 
disorders in the present study are some of the highest reported to date. The combined rate of 
schizophrenia and schizoaffective disorder was commensurate with previous findings (8, 9, 
14–16, 18, 24), although it is still higher than for individuals with 22q11.2 deletion 
syndrome ascertained in a nonpsychiatric setting (6).
The 10% of adolescents studied who qualified for a diagnosis of a psychotic disorder 
indicates that early-onset psychosis is relatively common in individuals with 22q11.2 
deletion syndrome who are referred for psychiatric research studies. Indeed, in a recent 
study the mean age at onset of psychotic disorders in youths with 22q11.2 deletion 
syndrome was 17.7 years (55). Psychotic disorder not otherwise specified was a somewhat 
more common diagnosis in children and adolescents than was schizophrenia. This may be 
because some young subjects do not meet the duration and/or severity criteria for a 
schizophrenia diagnosis and/or because of some reluctance to diagnose children with 
schizophrenia.
Sex Differences
Sex differences in the rates of several psychiatric disorders were comparable to those 
reported in the general population. Specifically, disruptive disorders and ADHD were more 
frequent in males than females, as documented in the general population (56, 57). There was 
a predominance of females among those diagnosed with anxiety and mood disorders as 
adults. Numerous studies have observed that sex differences in the rate of internalizing 
disorders emerge around puberty (58), suggesting the possible impact of hormonal changes 
in the development of affective symptoms in females.
In contrast, the male predominance of autism spectrum disorders and to a lesser extent 
psychotic disorders in the general population was not observed in 22q11.2 deletion 
syndrome. This may be related to the strong genetic contribution to the pathogenesis of 
social deficits and psychosis in 22q11.2 deletion syndrome and deserves investigation in 
future studies.
Intellectual Functioning, Adaptive Functioning, and Psychiatric Disorders
The associations among these variables were examined in a subgroup of participants with 
22q11.2 deletion syndrome (13%). This subgroup did not include adults age 25 or older, 
preventing the generalizability of the findings to older adults with the syndrome (28). The 
results showed that the presence of schizophrenia spectrum disorders was associated with 
lower intellectual functioning, whereas anxiety and mood disorders were not. This is 
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consistent with findings from the general population showing that schizophrenia spectrum 
disorders are associated with broad cognitive impairments (59).
On average, adaptive functioning scores were comparable to full-scale IQ in this subgroup 
(approximately two standard deviations below the means for the general population) and 
were significantly associated with the intellectual level. However, intellectual functioning 
explained only a small proportion of variance in adaptive functioning in this group of 
youths. This is consistent with a finding of no significant effect of IQ on adaptive 
functioning in a study of 78 children (25) but contrasts with the strong association between 
intellect and adaptive functioning in 100 adults with 22q11.2 deletion syndrome (28). The 
current study and these two previous studies also indicate that other factors contribute to 
adaptive functioning in this population. We found that older age was significantly associated 
with poorer socialization and communication skills, but psychotic, anxiety, or mood 
disorders did not affect socialization or communication. Longitudinal studies would be 
needed to determine if there is functional decline in some individuals and whether these 
deficits may precede the onset of psychiatric disorder. Other pathways could also lead to 
social and communication impairments in 22q11.2 deletion syndrome. Indeed, it has been 
shown that some cerebral regions involved in the development of social competence are 
altered and have an atypical developmental trajectory in 22q11.2 deletion syndrome (52). It 
is also possible that children with this condition may be socially motivated but fail to 
interact in a rewarding manner, leading to a more socially avoidant style and a reduction of 
social motivation and communication. This may explain the higher degree of social 
impairment during adolescence and adulthood.
Contrary to the results observed for communication and socialization skills, we found that, 
when the effects of age and full-scale IQ were controlled for, the presence of anxiety 
disorders was associated with poorer daily living skills and schizophrenia spectrum 
disorders had a nearly significant relationship, whereas mood disorders were not related to 
daily living skills. These relationships are consistent with previous findings and highlight the 
need for reducing the burden associated with psychiatric morbidity in 22q11.2 deletion 
syndrome (27, 28).
Suggestions for Clinical Management
The results suggest that in school-age children with 22q11.2 deletion syndrome, special 
emphasis is needed with regard to the diagnosis and management of attentional deficits, as 
these can interfere with learning and academic achievement. The presence of attentional 
deficits should be screened systematically and at regular intervals from the transition to 
elementary school onward (1). When ADHD is diagnosed, standard management options 
should be offered. Stimulants, as one of the treatment options, are effective and relatively 
well tolerated in children with 22q11.2 deletion syndrome (43), despite official warnings by 
health authorities against its use in individuals with cardiac anomalies. Monitoring of 
cardiovascular status during treatment should, however, be conducted. Learning may also be 
maximized by adjusting the child's school environment (small group teaching, promoting a 
quiet and highly structured environment).
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The emergence of social deficits during adolescence can represent a major source of 
disability in some individuals with 22q11.2 deletion syndrome. Interventions focusing on 
appropriate adaptation of social demands, such as introducing “buddies” as partners and 
mediators in social contacts, and stimulating participation in (structured) social activities 
should be considered. Future studies are needed to investigate the utility of sociocognitive 
remediation programs and cognitive-behavioral therapy to improve social skills.
The results also indicate that, as part of anticipatory care, individuals with 22q11.2 deletion 
syndrome should be screened for anxiety and mood disorders throughout their lifetimes. It is 
possible that successful management of anxiety and depression may be helpful in preventing 
or delaying the onset of psychotic disorders and reducing the severity of psychotic 
symptoms (18, 55). Recommended treatment strategies include effective cognitive-
behavioral and pharmacological approaches.
Given the markedly elevated risk for schizophrenia spectrum disorders, individuals with 
22q11.2 deletion syndrome should be closely monitored for prodromal and full-blown 
symptoms of psychosis. Negative symptoms being highly prevalent in adolescents with 
22q11.2 deletion syndrome (49), future studies should investigate the usefulness of omega-3 
polyunsaturated fatty acids in the reduction of prodromal symptoms (60). Clinically 
significant psychotic symptoms should be treated in accordance with the most recent 
recommendations for effective management. Antipsychotic medications are mainstays of 
treatment for schizophrenia spectrum disorders, as are psychoeducation, rehabilitation, and 
active stress reduction strategies.
In all cases, careful attention to and treatment of the comorbid medical conditions associated 
with 22q11.2 deletion syndrome that can mimic psychiatric illness or medication side 
effects, including hypocalcemia, hypothyroidism, and seizures, will help in optimizing 
psychiatric management (1).
Limitations and Conclusions
There are a number of limitations to this study. First, it is unknown how representative data 
on psychiatric research participants, even those in such a large consortium, would be for a 
true epidemiologic sample of people with 22q11.2 deletion syndrome. Children and 
adolescents were over-represented in this study group, likely because most research groups 
in the field of 22q11.2 deletion syndrome predominantly recruit children and adolescents 
with the syndrome and because it is known to be particularly underrecognized in adults (1). 
Indeed, the two oldest age groups of adults studied were about half the size of the three 
youngest age groups. In addition, this is a cross-sectional study and there is a need for large-
scale longitudinal studies to investigate the trajectories of psychiatric disorders from 
childhood to adulthood. Second, the reported rates of psychiatric disorders were based on 
different instruments across sites. For the small minority of subjects with severe intellectual 
disability, use of assessment tools tailored to persons with severe intellectual disability may 
be needed, in addition to the information from multiple informants and sources (parents, 
caregivers, and medical records) that is essential to the evaluation of any patient. 
Furthermore, no cross-site diagnostic reliability assessment was performed, and lack of such 
a measure could inflate the variability of the results. Third, only results for psychiatric 
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disorders meeting diagnostic criteria were presented. Future studies that include a 
dimensional examination of symptoms may better capture the full spectrum of 
psychopathology. Additional studies of at-risk mental states in this population would be 
particularly relevant. Finally, several important variables could not be taken into account in 
the results related to prevalence of psychiatric disorders. In particular, intellectual level, the 
presence of medical conditions, and treatment status were not available for all participants, 
although these factors, particularly intellectual level, may have significantly influenced the 
results. Also, information regarding the exact break points of the 22q11.2 deletion for each 
participant was not available for this study, which prevented examination of the influence of 
deletion size on the psychiatric phenotype. However, previous studies have shown that the 
vast majority of individuals with 22q11.2 deletion syndrome have the typical 3-Mb 22q11.2 
deletion, that there is no convincing evidence that phenotypic expression is related to the 
length of the deletion, and that there is no difference in the prevalence of the typical deletion 
between those with and without major psychiatric disorders, such as schizophrenia (1). The 
strengths of the study include the collaborative nature of the work, the large number of 
subjects, and the wide age range of the participants.
In conclusion, this study provides the prevalence of psychiatric disorders from childhood to 
adulthood in a group of more than 1,400 individuals with 22q11.2 deletion syndrome, a 
genetic condition associated with one of the highest risks known for developing 
schizophrenia. Such large-scale studies promise to help improve knowledge about 22q11.2 
deletion syndrome and in the future will provide data on key modifiers of psychiatric 
expression that could be generalizable to all forms of psychiatric illness.
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Figure 1. Age Distribution of 1,402 Participants With 22q11.2 Deletion Syndrome Assessed for 
Psychiatric Disorders
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Figure 2. Prevalence of Schizophrenia Spectrum Disorders and Distribution of Specific 
Disorders by Age in Participants With 22q11.2 Deletion Syndromea
a Among the 235 subjects with schizophrenia spectrum disorders, the prevalence of a 
schizophrenia diagnosis increased significantly over the age groups (χ2=12.54, df=4, 
p=0.01), whereas the diagnosis of psychotic disorder not otherwise specified decreased 
(χ2=17.17, df=4, p=0.002).
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